Scoop: With its NDA in lim­bo, Iron­shore ex­ecs shut­tered the AD­HD biotech

A year ago Iron­shore Phar­ma­ceu­ti­cals ex­ecs trum­pet­ed the news that they had lined up $200 mil­lion in fi­nanc­ing to launch a new AD­HD drug that would wow the field — des­tined to be­come a new stan­dard of care. They start­ed lin­ing up vet­er­an com­mer­cial and sci­en­tif­ic hires, an­tic­i­pat­ing an OK by the Ju­ly 30 PDU­FA date.

And then as the dead­line came and went the com­pa­ny was sud­den­ly as qui­et as the grave, de­clin­ing to say what the FDA had de­cid­ed as the agency main­tained the same si­lence it re­serves for all com­pa­ny mat­ters.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER